Cardiovascular
Can a Rubia extract protect hypoperfused rat brains?
Open access · cc by · source: Europe PMC
In 70 SD rats with 2VO hypoperfusion, 30-day RY-A gavage improved cognition and raised ferroptosis-guard proteins (SLC7A11, GPX4) via System Xc-/GSH/GPX4.
Study at a glance
- Design
- Animal / in-vitro — CCH (2VO) rat model with RY-A gavage, behavior/CBF/histology plus serum chemistry, RNA-seq, metabolomics, and Western blot
- N
- N=70 · 70 male Sprague-Dawley rats (260 ± 20 g, 8 weeks); Sham n=12; 52 successful 2VO models
- Population
- Male Sprague-Dawley rats with bilateral carotid 2-vessel occlusion chronic cerebral hypoperfusion
- Outcome
- Cognition (Morris water maze), cerebral blood flow, histology, ferroptosis/oxidative-stress proteins (SLC7A11, GPX4, etc.)
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
RY-A attenuated neurological damage and improved cognition. UHPLC-HRMS found 511 blood-entry compounds. RY-A increased SLC7A11, SLC3A2, GSS, and GPX4, boosted antioxidant enzymes, and authors conclude it inhibited ferroptosis by activating System Xc-/GSH/GPX4 and balancing iron.
Methodology
After 2VO CCH modeling, treated rats with RY-A gavage for 30 days, then Morris water maze, CBF, HE staining, serum medicinal chemistry, RNA-seq, metabolomics, assay kits, and Western blots.
Limitations
Rat 2VO data do not prove RY-A treats human vascular dementia; doses and 511 compounds are preclinical leads, not a clinical trial.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.